解码翰森制药的创新DNA:趟出一条中国医药产业逆袭之路

健识局
Dec 31, 2025

2025年初冬,翰森制药传出振奋行业的暖讯:授予印度药企Glenmark独占许可,允许其在中东与非洲、东南亚与南亚、澳大利亚、新西兰、俄罗斯、部分特定加勒比国家及其他独联体国家开发和商业化阿美替尼。这份总额超10亿美元的重磅合作,让阿美替尼的版图一举拓宽至20余个国家和地区,为翰森出海之路再度破冰,同时也把翰森制药再度推到聚光灯下。核心单品领跑:阿美替尼海内外双线突破2025年是阿美替尼在国际市场...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10